Reply to thread

Message: <blockquote data-quote="imhotep" data-source="post: 29007535" data-attributes="member: 562115">At least a very good start of a new hope for cancer patients. Have to see how it goes on the human trials.<a href="https://imgbox.com/c9cW9meF" target="_blank"><img src="https://thumbs2.imgbox.com/dd/07/c9cW9meF_t.jpg" alt="" class="fr-fic fr-dii fr-draggable " style="" /></a>The report states....At-211 decays with a half-life of 7.21 hours in two branches, either by α-emission to Bismuth-207 (207Bi) or by electron capture (EC) to Polonium-211 (211Po). After the EC, 211Po promptly decays by α-emission to the stable lead-207 (207Pb). This process demonstrates that each decay will yield one α particle. In addition, the EC branch to 211Po will deliver characteristic Polonium X-rays in the range of 70–90 keV. This process enables simple quantification, and the energy of the X-rays is in the field where it can be imaged with a γ camera.Therefore, by attaching At-211 to molecules designed to target specific cancer cells, we could develop an anticancer therapy that should cause minor damage to surrounding healthy tissue compared with the effects of current chemotherapy and radiation therapy.</blockquote>

Top Bottom